– USA, IL – Walgreens Boots Alliance, Inc. (Nasdaq: WBA) today announced the appointment of Steve Shulman to its board of directors, effective Jan. 27, 2022.
“Steven is a tremendous addition to our board of directors. His vast leadership experience and in-depth knowledge across the healthcare spectrum will be invaluable as we move into our next phase of being a market leader at the center of community healthcare,” said Executive Chairman, Stefano Pessina.
CEO Roz Brewer added: “We are very pleased to welcome Steven to our board. We look forward to benefiting from his industry expertise and viewpoints on the evolving healthcare landscape, as we continue to execute our consumer-centric healthcare strategy and drive long-term shareholder value.”
About Steve Shulman
Steve Shulman brings a wealth of healthcare management experience, as well as an extensive leadership background in emerging healthcare technologies. He currently serves on the boards at both VillageMD and CareCentrix, two companies in which WBA has recently taken a majority ownership interest. Shulman will provide valuable insights and a unique perspective to the WBA board as the company accelerates efforts to reimagine local healthcare delivery.
Shulman currently serves as the Chairman of CareCentrix, Inc. and SOC Telemed; he also serves as co-Chairman of HealthMap Solutions and as Lead Director of VillageMD. He is a director of several other privately held companies, including Facet Technologies, Ensemble Healthcare Partners and Pager, Inc. Shulman is also Managing Partner at Shulman Family Ventures, Inc., a private equity firm.
His prior healthcare leadership experience includes roles as Chairman and CEO of Magellan Health Services, Inc. He previously served as Chairman and CEO of Internet Healthcare Group, LLC and as Chairman, President, and CEO of Prudential Healthcare, where he was also Director and President of the Pharmacy and Disease Management Group. Shulman held senior positions at Cigna Corporation, including President of the East Central Division, and Kaiser Permanente, including Director, Medical Economics. He served as Chairman of the Board of Directors of R1 RCM, Inc. and Health Management Associates, Inc.
“I am honored to join the Walgreens Boots Alliance board at an exciting and pivotal time, and look forward to working with the board and leadership team to further the great momentum they’ve built,” commented Steven Shulman. “I am confident WBA will make an even greater impact in the communities it serves, by improving access and health outcomes, while lowering the total cost of care.”
About Walgreens Boots Alliance
Walgreens Boots Alliance is integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 170-year heritage of caring for communities.
A trusted, global innovator in retail pharmacy with approximately 13,000 locations across the U.S., Europe, and Latin America, WBA plays a critical role in the healthcare ecosystem. The company is reimagining local healthcare and well-being for all as part of its purpose – to create more joyful lives through better health. Through dispensing medicines, improving access to a wide range of health services, providing high-quality health and beauty products, and offering anytime, anywhere convenience across its digital platforms, WBA is shaping the future of healthcare.
WBA has more than 315,000 team members and a presence in nine countries through its portfolio of consumer brands: Walgreens, Boots, Duane Reade, the No7 Beauty Company, Benavides in Mexico, and Ahumada in Chile. Additionally, WBA has a portfolio of healthcare-focused investments located in several countries, including China and the U.S.
For more information: https://www.walgreensbootsalliance.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
